BioTime, Inc.  Company Profile

10:26 EST 23rd January 2019 | BioPortfolio

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® in the EU is expected to be early 2018, with possible approval and commercial launch in 2018. There were no device related serious adverse events reported. OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

News Articles [50 Associated News Articles listed on BioPortfolio]

BioTime Acquires Two Clinical─Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno─Oncology

BioTime, Inc, and Asterias Biotherapeutics, Inc, announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Aster...

BioTime, Orbit Biomedical team up in dry-AMD

In an exclusive twelve-month deal, BioTime Inc. and start-up Orbit Biomedical Ltd. are collaborating on the delivery of BioTime’s dry age-related macular degeneration candidate using Orbit’s techn...

Asterias Biotherapeutics to merge with BioTime

US-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed...Read More... The post Asterias Biotherapeutic...

BioTime spins out its early-stage technology into new company

BioTime Inc (NYSEAMERICAN:BTX) CEO Brian Culley sat down with Proactive Investors at the 11th Annual LD Micro Main Event in Los Angeles.  BioTime specializes in regenerative medicine and util...

Biotechnology firm BioTime to secure $43m from Juvenescence

Under the terms of the agreement, Juvenescence will purchase, in a single transaction, 14.4 million shares of AgeX Therapeutics from BioTime for $43.2 million. 50% of the purchase The post Biotechnol...

BioTime signs merger deal with Asterias Biotherapeutics

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common The post BioTime signs m...

BioTime schließt Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab

Erlös stellt BioTime ausreichend Kapital für die Finanzierung wichtiger Meilensteine aktueller Programme zur Verfügung, einschließlich Schlüsseldaten und Entscheidungen zu Renevia und OpRegen Bio...

Asterias and BioTime reverse merge to focus on cancer, neuro cell therapies

BioTime Inc. is re-acquiring an ownership stake in former subsidiary Asterias Biotherapeutics Inc., resulting in a merged cell therapy company in which Asterias will be the surviving entity and hold 1...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [9 Associated Companies listed on BioPortfolio]

BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell techn...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s p...

BioTime, Inc. and Abcodia Ltd.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell ...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical ...

BioTime Incorporated

BioTime, Inc. (OTCBB: BTIM), based in Emeryville, California, is engaged in the research and development of aqueous-based synthetic solutions that may be used as plasma expanders, organ preservation s...

More Information about "BioTime, Inc. " on BioPortfolio

We have published hundreds of BioTime, Inc.  news stories on BioPortfolio along with dozens of BioTime, Inc.  Clinical Trials and PubMed Articles about BioTime, Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioTime, Inc.  Companies in our database. You can also find out about relevant BioTime, Inc.  Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Corporate Database Quicklinks

Searches Linking to this Company Record